Recombinant CD38 (Daratumumab Biosimilar) anticorps

N° du produit ABIN7795093

Cet anticorps anti-CD38 (Daratumumab Biosimilar) est un anticorps Souris Monoclonal détectant CD38 (Daratumumab Biosimilar) dans FACS et in vivo. Adapté pour Humain.

Aperçu rapide pour Recombinant CD38 (Daratumumab Biosimilar) anticorps (ABIN7795093)

Antigène: CD38 (Daratumumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD38 (Daratumumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD38 (Daratumumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Daratumumab Biosimilar, CD38 Monoclonal Antibody

Attributs du produit: Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab. Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD38

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD38 (Daratumumab Biosimilar)

Antigène: CD38 (Daratumumab Biosimilar)

Autre désignation: Daratumumab Biosimilar

Classe de substances: Biosimilar